Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ITI-333 PET Receptor Occupancy Study
NCT05470101Phase 1Completed
- Sponsor
- Intra-Cellular Therapies
- Start
- Jul 2022
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ITI-333 in opioid use disorder (OUD) and pain (4 cohorts), sponsored by Intra-Cellular Therapies. Primary endpoints: 5-HT2A receptor occupancy, Area under the concentration-time curve from time zero to the last measurable concentration and 2 more. Started Jul 2022; status: completed.
02
Drugs
ITI-333
03
Conditions
opioid use disorder (OUD)pain
Beyond the preview
Go deeper on NCT05470101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05470101.